CAR-T Cell Therapy Market By Therapy Type (Autologous CAR T-Cell Therapy, Allogeneic CAR T-Cell Therapy), By Indication (Hematologic Malignancies {Leukemia, Lymphoma, Myeloma} Solid Tumors {Ovarian Cancer, Lung Cancer}), By End-User (Hospitals, Cancer Research Institutes, Academic & Research Centers, Specialty Clinics), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

• By Therapy Type
  • Autologous CAR T-Cell Therapy
  • Allogeneic CAR T-Cell Therapy
• By Indication
  • Hematologic Malignancies
    • Leukemia
    • Lymphoma
    • Myeloma
  • Solid Tumors
    • Ovarian Cancer
    • Lung Cancer
• By End-User
  • Hospitals
  • Cancer Research Institutes
  • Academic & Research Centers
  • Specialty Clinics

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Novartis International AG
• Gilead Sciences, Inc.
• Bristol Myers Squibb
• Pfizer Inc.
• Johnson & Johnson
• Amgen Inc.
• Legend Biotech Corporation
• Bluebird Bio Inc.
• Cellectis S.A.
• Allogene Therapeutics Inc.
• Caribou Biosciences Inc.
• Intellia Therapeutics Inc.
• Adaptimmune Therapeutics plc
• Poseida Therapeutics Inc.
• Autolus Therapeutics plc
• Sorrento Therapeutics, Inc.
• Mustang Bio Inc.
• Bellicum Pharmaceuticals